Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.33 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6545278 | 0.91 | TSHR (0.38) | TSHR | |
| SCHEMBL4921832 | 0.83 | EGLN1 (0.42) | TSHRLMNAKDM4EALDH1A1VCAM1 | |
| SCHEMBL6545080 | 0.83 | TSHR (0.42) | TSHRLMNAALDH1A1RECQLGLA | |
| SCHEMBL28163566 | 0.82 | MGAM (0.35) | TSHRMGAMGAASIMGAM2 | |
| SCHEMBL6309457 | 0.81 | ALDH1A1 (0.46) | TSHRLMNAALDH1A1 | |
| SCHEMBL20168030 | 0.78 | TSHR (0.46) | TSHRLMNAKDM4EALDH1A1KMT2A | |
| SCHEMBL11905663 | 0.77 | TSHR (0.32) | TSHRCA12CA14RECQL | |
| SCHEMBL12227359 | 0.77 | LDHA (0.33) | TSHR | |
| SCHEMBL12540531 | 0.76 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL26108395 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912953-B1 | PROCESS FOR THE SYNTHESIS OF ROSUVASTATIN CALCIUM | LEK PHARMACEUTICALS (SI) | 2016-08-17 | — | — | EP | disclosed |
| US-8354530-B2 | Preparation of HMG-CoA reductase inhibitors, in particular rosuvastatin calcium, introducing L-malic acid as source of chirality for side chain; statin core moiety is consecutively coupled with chiral segment containing 4 carbon atoms and segment containing 2 carbon atoms; treating hypercholesterolemia | Lek Pharmaceuticals d. d (SI) | 2013-01-15 | — | — | US | disclosed |
| US-20080255170-A1 | Process for the Synthesis of Rosuvastatin Calcium | LEK PHARMACEUTICALS D.D (SI) | 2008-10-16 | — | — | US | disclosed |
| EP-1912953-A1 | PROCESS FOR THE SYNTHESIS OF ROSUVASTATIN CALCIUM | LEK Pharmaceuticals D.D. (SI) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007017117-A1 | PROCESS FOR THE SYNTHESIS OF ROSUVASTATIN CALCIUM | LEK PHARMACEUTICALS D.D. (SI) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255170-A1 | Process for the Synthesis of Rosuvastatin Calcium | HMGCR, ME1, COASY | TSHR 4795/4885LMNA 555/4885KDM4E 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.